Display options
Cite
Spoor JKH, Greco T, Kamp MA, et al. Quantifying the burden of disease in patients with Lennox Gastaut syndrome. Epilepsy Behav Rep. 2021;16:100508doi: 10.1016/j.ebr.2021.100508.
Spoor, J. K. H., Greco, T., Kamp, M. A., Faini, S., Senft, C., & Dibué, M. (2021). Quantifying the burden of disease in patients with Lennox Gastaut syndrome. Epilepsy & behavior reports, 16100508. https://doi.org/10.1016/j.ebr.2021.100508
Spoor, Jochem K H, et al. "Quantifying the burden of disease in patients with Lennox Gastaut syndrome." Epilepsy & behavior reports vol. 16 (2021): 100508. doi: https://doi.org/10.1016/j.ebr.2021.100508
Spoor JKH, Greco T, Kamp MA, Faini S, Senft C, Dibué M. Quantifying the burden of disease in patients with Lennox Gastaut syndrome. Epilepsy Behav Rep. 2021 Nov 25;16:100508. doi: 10.1016/j.ebr.2021.100508. eCollection 2021. PMID: 34917922; PMCID: PMC8666633.
Copy Download .nbib Format: NLM
Share it on

Epilepsy Behav Rep. 2021 Nov 25;16:100508. doi: 10.1016/j.ebr.2021.100508. eCollection 2021.

Quantifying the burden of disease in patients with Lennox Gastaut syndrome.

Epilepsy & behavior reports

Jochem K H Spoor, Teresa Greco, Marcel A Kamp, Silvia Faini, Christian Senft, Maxine Dibué

Affiliations

  1. Department of Neurosurgery, Erasmus University, Dr. Molewaterplein 40, 3015 GD, Rotterdam, Netherlands.
  2. Statistics and Data Management, LIVANOVA - SORIN Group Italia S.r.l., Via Benigno Crespi, 17, 20159 Milano, Italy.
  3. Department of Neurosurgery, Medical Faculty, Friedrich Schiller University, Fürstengraben 1, 07743 Jena, Germany.
  4. Medical Affairs International, Neuromodulation, LivaNova PLC, 20 Eastbourne Terrace, London W2 6LG United Kingdom.

PMID: 34917922 PMCID: PMC8666633 DOI: 10.1016/j.ebr.2021.100508

Abstract

Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy but there is limited literature characterizing the disease burden despite this being crucial for disease management strategies, and for designing and interpreting clinical trials. We searched the Vagus Nerve Stimulation (VNS) Therapy Patient Outcome Registry including over 7000 patients with drug‑resistant epilepsy (DRE). Propensity Score Matching (PSM) matched LGS-DRE patients and non-LGS-DRE patients and frequencies of individual seizure types were assessed. The PSM population included 705 and 1410 DRE patients with and without LGS. 40% of the LGS-DRE group had polypharmacy with 3 antiseizure medications (ASM) while 42% in non-LGS-DRE had polypharmacy with 2 ASMs. Median total monthly seizure frequency was over double in the LGS group: 90 (IQR, 28-312) versus 40 (IQR, 10-150); p < 0.001. This analysis suggests that seizure frequency in LGS patients who later receive VNS is more than double than in non-LGS DRE patients with mostly bilateral tonic-clonic seizures contributing to this difference. Furthermore, ASM burden with poorer seizure control may be greater in LGS patients, however data collection ceased in 2003 and therefore does not take recent ASMs approved for LGS into account. This analysis offers quantitative insight into the burden of disease in patients with LGS.

© 2021 The Authors.

Keywords: ASM, antiseizure medication; Drug-resistant epilepsy; Epileptic encephalopathy; LGS, Lennon-Gastaut Syndrome; Lennox–Gastaut Syndrome; Seizure types; VNS; VNS, vagus nerve stimulation; Vagus nerve stimulation

References

  1. PLoS Med. 2015 Oct 06;12(10):e1001885 - PubMed
  2. N Engl J Med. 2018 May 17;378(20):1888-1897 - PubMed
  3. J Multidiscip Healthc. 2014 Oct 04;7:441-8 - PubMed
  4. Front Neurol. 2017 Sep 29;8:505 - PubMed
  5. Neurosurgery. 2004 Nov;55(5):1086-93 - PubMed
  6. Int J Surg. 2014 Dec;12(12):1495-9 - PubMed

Publication Types